Zoe X. Malchiodi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zoe X. Malchiodi has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Louis M. Weiner
Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States
31 shared publications - Sandra A. Jablonski
Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia
30 shared publications - Elana Judith Fertig
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
26 shared publications - Brent T. Harris
Georgetown University Medical Center 5 Department of Pathology Washington, District of Columbia
25 shared publications - Robert K. Suter
Georgetown University Medical Center 1 Lombardi Comprehensive Cancer Center Washington, District of Columbia
25 shared publications - Won Jin Ho
Johns Hopkins University 4 Department of Oncology, School of Medicine Baltimore, Maryland
25 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits dense fibrosis and immune exclusion. Although fibrosis has been studied globally and at the region-of-interest level, its impact on stromal–ductal architecture and immune cell localization remains unknown. In this study, we establish cancer-associated fibroblast (CAF)–stratified ductal spatial architecture as a fundamental determinant of immune exclusion in PDAC. Focusing on malignant PDAC epithelial ductal regions, the critical interface in which immune cells must access tumor epithelium, we demonstrate that periductal fibroblast organization dictates leukocyte proximity. Through integrative analysis of treatment-naïve patient samples from three independent cohorts—including imaging mass cytometry, multiplex immunohistochemistry, and single-cell RNA sequencing—we uncover that activated, proinflammatory leukocytes preferentially localize near malignant ducts in regions with low fibroblast density. Stratifying epithelial ductal regions by CAF abundance reveals a graded constraint: increasing fibroblast content corresponds to reduced leukocyte–epithelial proximity and elevated collagen I deposition. Despite their exclusion in high-CAF ducts, leukocytes in low-CAF ducts retain functional competence. Mechanistically, ligand–receptor inference implicates collagen–CD44 signaling as an adhesion axis anchoring immune cells within fibroblast-rich zones. CD44 blockade augments natural killer cell motility in vitro, whereas enhancing lymphocyte collagenase activity through matrix metalloproteinase 14 (MMP14) overexpression promotes infiltration by overcoming alpha smooth muscle actin (αSMA+) CAF-mediated stromal barriers in vivo. Thus, by establishing ductal regions as critical spatial units of immune exclusion, these findings provide a framework for dissecting stromal–immune interactions, reveal targetable “stromal checkpoints,” and provide complementary strategies to overcome CAF-driven barriers to leukocyte motility and infiltration in PDAC.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits dense fibrosis and immune exclusion. Although fibrosis has been studied globally and at the region-of-interest level, its impact on stromal–ductal architecture and immune cell localization remains unknown. In this study, we establish cancer-associated fibroblast (CAF)–stratified ductal spatial architecture as a fundamental determinant of immune exclusion in PDAC. Focusing on malignant PDAC epithelial ductal regions, the critical interface in which immune cells must access tumor epithelium, we demonstrate that periductal fibroblast organization dictates leukocyte proximity. Through integrative analysis of treatment-naïve patient samples from three independent cohorts—including imaging mass cytometry, multiplex immunohistochemistry, and single-cell RNA sequencing—we uncover that activated, proinflammatory leukocytes preferentially localize near malignant ducts in regions with low fibroblast density. Stratifying epithelial ductal regions by CAF abundance reveals a graded constraint: increasing fibroblast content corresponds to reduced leukocyte–epithelial proximity and elevated collagen I deposition. Despite their exclusion in high-CAF ducts, leukocytes in low-CAF ducts retain functional competence. Mechanistically, ligand–receptor inference implicates collagen–CD44 signaling as an adhesion axis anchoring immune cells within fibroblast-rich zones. CD44 blockade augments natural killer cell motility in vitro, whereas enhancing lymphocyte collagenase activity through matrix metalloproteinase 14 (MMP14) overexpression promotes infiltration by overcoming alpha smooth muscle actin (αSMA+) CAF-mediated stromal barriers in vivo. Thus, by establishing ductal regions as critical spatial units of immune exclusion, these findings provide a framework for dissecting stromal–immune interactions, reveal targetable “stromal checkpoints,” and provide complementary strategies to overcome CAF-driven barriers to leukocyte motility and infiltration in PDAC.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S10: Human donor NK cells express CD44.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S10: Human donor NK cells express CD44.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S1: Spatial proteomic analysis of the human PDAC TME resolves PDAC cell populations.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S1: Spatial proteomic analysis of the human PDAC TME resolves PDAC cell populations.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S11: Effects of CD44 blockade on NK cell invasion through fibronectin and laminin matrices in vitro.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S11: Effects of CD44 blockade on NK cell invasion through fibronectin and laminin matrices in vitro.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S12: CD44 neutralization increases human donor NK cell invasion into PANC-1 PDAC spheroids.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S12: CD44 neutralization increases human donor NK cell invasion into PANC-1 PDAC spheroids.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S13: CD44 neutralization does not impact NK cell cytotoxicity or ADCC in vitro.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S13: CD44 neutralization does not impact NK cell cytotoxicity or ADCC in vitro.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S3: Proportions of PDAC subclustered cell populations per cellular neighborhood.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S3: Proportions of PDAC subclustered cell populations per cellular neighborhood.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S14: CD44 neutralization does not affect expression of MMP genes in human donor NK cells.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S14: CD44 neutralization does not affect expression of MMP genes in human donor NK cells.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S15: CD44 neutralization does not affect expression of MMP proteins in primary human NK cells.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S15: CD44 neutralization does not affect expression of MMP proteins in primary human NK cells.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S2: Subclustered cell populations of spatial proteomic resolved PDAC cell populations.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Supplementary Figure S2: Subclustered cell populations of spatial proteomic resolved PDAC cell populations.